Transformational Innovation from Elixir Medical - Elixir Medical
We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come. We developed the world’s first site-specific antithrombotic therapy using two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor, sirolimus. Our drive and pursuit of the impossible led to innovations such as the DynamX® Coronary Bioadaptor System. At Elixir we believe that only by harnessing the power of transformation can there be real-world impact. At Elixir we believe that only by harnessing the power of transformation can there be real world impact. By disrupting the status quo, we are going where others have given up. DynamX bioadaptor is a coronary implant that is uniquely designed to not only restore blood flow, but to also unlock and uncage the vessel, allowing the artery to return to its natural physiology, motion and function while DynamX continues to provide dynamic support. Designed with deliverability, safety and simplicity of use in mind.
Verified
Drug Portfolio for Elixir Medical's Clinical Programs - Elixir Medical
Elixir's drug portfolio includes Novolimus and Sirolimus, which have been studied as part of Elixir Medical’s Clinical Programs.
Verified
mTOR inhibitors from Elixir Medical - Elixir Medical
Novolimus and Sirolimus are mTOR inhibitors that have been studied as part of Elixir Medical's clinical trials for DynamX and DESyne.
Verified
Elixir Medical Announces Outstanding Long-Term Clinical Results at EuroPCR for World’s Broadest Portfolio of Three CE Mark-Approved Novolimus Eluting Coronary Intervention Systems - Elixir Medical
CE Mark-Approved DESyne® Novolimus Eluting Coronary Stent System is Superior in Safety and Efficacy at the 5-year Endpoint in the EXCELLA II Randomized Clinical Trial Three-Year Results from the EXCELLA BD Randomized Clinical Trial for the CE Mark-Approved DESyne BD System with Biodegradable Polymer Coating Continues Reporting No Stent Thrombosis Excellent Eighteen-Month DESolve Nx Trial Results […]
View all products
Keywords
Industries
Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR - Elixir Medical
Sunnyvale, CA —May 21, 2014—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that the successful live case demonstration of its breakthrough DESolve® 100 Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the “Multivessel PCI: Whats’s new?” session at EuroPCR in Paris. EuroPCR is the official annual meeting […]
How many employees does Elixir Medical approximately have?
As of the latest available information Elixir Medical has around 51-100 employees worldwide.
When was Elixir Medical founded?
Elixir Medical was founded in 2004
In which industries does Elixir Medical mainly work?
The company Elixir Medical has it's main focus in the industries of Health Care
What is the current company status of Elixir Medical?
Based on the founding year and the amount of employees the company Elixir Medical seems to be a Medium-Sized Company at the current state. Note that over time that status can change
Adient Medical
United States
1-10 Employees
2012
Thrombolex Inc.
United States
11-50 Employees
2016
Exelixis
United States
251-500 Employees
1994
Medinol
Israel
251-500 Employees
1992
MEDA Angels
United States
1-10 Employees
2019
XtremedX LLC
United States
1-10 Employees
2018
ELUTE
United States
1-10 Employees
2011
Evysio Medical Devices ULC
Canada
11-50 Employees
1997
Topics which have been searched by others and may be interesting for you:
